Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in … (Centre Daily Times)
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the presentation of Phase 3 data at the annual Digestive Disease Week (DDW) Congress on GATTEX(TM) (teduglutide), a novel investigational compound that may reduce dependence upon parenteral nutrition (PN) in patients with intestinal failure associated with short bowel syndrome (SBS).